# GRCE catalysts: Grace Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/grce/catalysts

> Grace Therapeutics, Inc. (GRCE) has 3 upcoming catalysts. The next is the GS-100 primary completion, March 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Grace Therapeutics, Inc. |
| Ticker | GRCE (Nasdaq) |
| SEC CIK | 1444192 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/grce |

## Cash runway

Cash $21.3M as of 2026-09-30; quarterly burn $1.8M; about 35.8 months of runway at that rate (XBRL company facts, accession 0001140361-26-043299).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2021 | [Nimodipine trial start](https://sec-api.dev/pdufa/nimodipine) | GRCE |  | completed | "In September 2021, we initiated our pivotal PK bridging trial to evaluate the relative bioavailability of GTx-104 compared to currently marketed oral nimodipine capsules in approximately 50 healthy subjects." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1444192/000114036124046312/ef20037228_10q.htm)) |
| Dec 2022 | [Soluspan® (betamethasone) topline data readout](https://sec-api.dev/pdufa/betamethasone) | GRCE |  | completed, met | "In December 2022, we reported that the topline results of this trial met all primary outcome measures." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1444192/000114036125041804/ef20054994_10q.htm)) |
| November 13, 2024 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced financial results and business highlights for the quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/ef20038398_ex99-1.htm)) |
| Q1 2025 | [Nimodipine topline data readout](https://sec-api.dev/pdufa/nimodipine) | GRCE |  | scheduled | ""With enrollment in the STRIVE-ON trial now complete, we anticipate a data readout in first calendar quarter of 2025, and remain on track to submit a New Drug Application (NDA) to the U.S. Food Drug Administration in the first half of calendar 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/ef20038398_ex99-1.htm)) |
| February 13, 2025 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "patients, today announced financial results and business highlights for the quarter ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125004157/ef20043203_ex99-1.htm)) |
| Jun 2025 | [GTX-104 NDA/BLA submission](https://sec-api.dev/pdufa/gtx-104) | GRCE |  | scheduled | ""Our focus now is to finalize our NDA submission for GTx-104, which we expect to complete by the end of June 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125023261/ef20050698_ex99-1.htm)) |
| June 23, 2025 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces 2025 Fiscal Year-End Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125023261/ef20050698_ex99-1.htm)) |
| August 12, 2025 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces First Quarter 2026 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_ex99-1.htm)) |
| August 22, 2025 | [GTX-104 NDA/BLA acceptance](https://sec-api.dev/pdufa/gtx-104) | GRCE |  | completed | "On August 22, 2025, the FDA accepted the Company's NDA for GTx-104 for formal review, establishing April 23, 2026 as its PDUFA target date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm)) |
| August 27, 2025 | [Nimodipine NDA/BLA acceptance](https://sec-api.dev/pdufa/nimodipine) | GRCE |  | completed | "Princeton, NJ, August 27, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that on August 22, 2025 the U.S. Food and Drug Administration (FDA) accepted the Company's New Drug Application (NDA) for GTx-104 for formal review." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/ef20054617_ex99-1.htm)) |
| November 13, 2025 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces Second Quarter 2026 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm)) |
| February 12, 2026 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces Third Quarter 2026 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/ef20064916_ex99-1.htm)) |
| April 23, 2026 | [Grace Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed, complete response letter | "April 23, 2026, the Company received a CRL from the FDA in response to their" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1444192/000114036126025662/ef20070498_10k.htm)) |
| April 23, 2026 | [Grace Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | scheduled | "On August 22, 2025, the FDA accepted our NDA for review and established April 23, 2026 as the PDUFA target date for completing its review of our submission." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1444192/000114036126004924/ef20060621_10q.htm)) |
| April 23, 2026 | [Nimodipine NDA/BLA submission](https://sec-api.dev/pdufa/nimodipine) | GRCE |  | scheduled | "The FDA established a Prescription Drug User Fee Act (PDUFA) target date of April 23, 2026 for its review of the Company's NDA submission." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/ef20054617_8k.htm)) |
| April 23, 2026 | [Nimodipine complete response letter (CRL)](https://sec-api.dev/pdufa/nimodipine) | GRCE | with aSAH | completed, complete response letter | "Princeton, NJ, April 23, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's New Drug Application (NDA) for GTx-104 for the treatment of patients with aSAH." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126016324/ef20070593_ex99-1.htm)) |
| April 23, 2026 | [GTX-104 PDUFA date](https://sec-api.dev/pdufa/gtx-104) | GRCE | aSAH | completed, complete response letter | "FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/ef20064916_ex99-1.htm)) |
| April 23, 2026 | [GTX-104 complete response letter (CRL)](https://sec-api.dev/pdufa/gtx-104) | GRCE | with aSAH | completed, complete response letter | "On April 23, 2026, the FDA issued a CRL for the Company's NDA for GTx-104 for the treatment of patients with aSAH." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_ex99-1.htm)) |
| April 23, 2026 | [Nda220304 complete response letter (CRL)](https://sec-api.dev/pdufa/nda220304) | GRCE |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220304_20260423_Redacted.pdf%22)) |
| June 18, 2026 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_ex99-1.htm)) |
| Jul 2026 | [Grace Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed, complete response letter | "Following a Type A meeting with the FDA regarding the CRL, we received the FDA's official meeting minutes in July 2026, constituting the official record of the meeting." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1444192/000114036126043299/ef20080550_10q.htm)) |
| July 28, 2026 | [Nimodipine complete response letter (CRL)](https://sec-api.dev/pdufa/nimodipine) | GRCE |  | completed, complete response letter | "Princeton, NJ, July 28, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced receipt of the U.S. Food and Drug Administration (FDA) meeting minutes from a Type A Meeting held with the FDA to discuss the Complete Response Letter (CRL) issued on April 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_ex99-1.htm)) |
| August 13, 2026 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces First Quarter 2027 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/ef20079525_ex99-1.htm)) |
| November 12, 2026 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces Second Quarter 2027 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126043308/ef20085030_ex99-1.htm)) |
| March 2027 | [GS-100 primary completion](https://sec-api.dev/pdufa/gs-100) | GRCE | NGLY1 Deficiency | scheduled | "NCT06199531 (Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Grace Science, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06199531)) |
| Mar to Jun 2027 | [GS-100 topline data readout](https://sec-api.dev/pdufa/gs-100) | GRCE | NGLY1 Deficiency | scheduled | "NCT06199531 (Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Grace Science, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06199531)) |
| September 25, 2028 | [GTX-104 NDA/BLA acceptance](https://sec-api.dev/pdufa/gtx-104) | GRCE |  | scheduled | "These warrants are currently exercisable and will expire on the earlier of (i) the 60th day after the date of the acceptance by the FDA of an NDA for the Company's product candidate GTX-104 or (ii) September 25, 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/ef20054617_ex99-1.htm)) |

## Drugs

- [Soluspan® (betamethasone)](https://sec-api.dev/pdufa/betamethasone): 
- [GS-100](https://sec-api.dev/pdufa/gs-100): NGLY1 Deficiency
- [GTX-104](https://sec-api.dev/pdufa/gtx-104): asah, with asah, with aneurysmal subarachnoid hemorrhage
- [Nda220304](https://sec-api.dev/pdufa/nda220304): 
- [Nimodipine](https://sec-api.dev/pdufa/nimodipine): with asah

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/grce/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GRCE catalysts: Grace Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/grce/catalysts

```bibtex
@misc{secapidev_companies_grce_catalysts_20261116,
  title        = {GRCE catalysts: Grace Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/grce/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_grce_catalysts_20261116","title":"GRCE catalysts: Grace Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/grce/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
